Sciatic Nerve Block with Ropivacaine and Prilocaine in a Patient with Chronic Progressive External Ophthalmoplegia (CPEO)

DOI: 10.4236/ojanes.2012.24027   PDF   HTML   XML   4,373 Downloads   6,658 Views  

Abstract

The anesthetic implications of caring for patients with mitochondrial myopathies (MM) are not well defined, and the few case reports that have been published are contradictory. Local anesthetics particularly have the potential to worsen neuromuscular manifestations via direct effects on mitochondrial bioenergetics. Here we describe the anesthetic management of a patient with chronic progressive external ophthalmoplegia (CPEO) in which a sciatic nerve block with ropivacaine and prilocaine was performed and review the available related literature.

Share and Cite:

H. Baumann, E. Schlegel, F. Wagner and J. Biscoping, "Sciatic Nerve Block with Ropivacaine and Prilocaine in a Patient with Chronic Progressive External Ophthalmoplegia (CPEO)," Open Journal of Anesthesiology, Vol. 2 No. 4, 2012, pp. 117-119. doi: 10.4236/ojanes.2012.24027.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] K. Nouette-Gaulain, C. Jose, X. Capdevila and R. Rossignol, “From Analgesia to Myopathy: When Local Anesthetics Impair the Mitochondrion,” The International Journal of Biochemistry & Cell Biology, Vol. 43, No. 1, 2011, pp. 14-19. doi:10.1016/j.biocel.2010.10.005
[2] E. A. Shipton and D. O. Prosser, “Mitochondrial Myopathies and Anaesthesia,” European Journal of Anaesthesiology, Vol. 21, 2004, pp. 173-178.
[3] R. M. Fricker, T. Raffelsberger, S. Rauch-Shorny, J. Finsterer, C. Muller-Reible, H. Gilly and R. E. Bittner, “Positive Malignant Hyperthermia Susceptibility in Vitro Test in a Patient with Mitochondrial Myopathy and Myoadenylate Deaminase Deficiency,” Anesthesiology, Vol. 97, No. 6, 2002, pp. 1635-1637. doi:10.1097/00000542-200212000-00044
[4] Y. Ohtani, T. Miike and T. Ishitsu, “A Case of Malignant Hyperthermia with Mitochondrial Dysfunction (Letter),” Brain & Development, Vol. 7, 1985, p. 249.
[5] A. M. Burns and M. P. Shelly, “Anaesthesia for Patients with Mitochondrial Myopathy,” Anaesthesia, Vol. 44, No. 12, 1989, pp. 975-977. doi:10.1111/j.1365-2044.1989.tb09200.x
[6] E. Guasch, B. Civantos, J. M. Aguilar, M. D. Torres, F. Gilsanz, “Progressive External Ophthalmoplegia and Ambulatory Remifentanil-Propofol Based Anaesthesia,” Anaesthesia, Vol. 58, No. 6, 2003, pp. 607-608. doi:10.1046/j.1365-2044.2003.32191.x
[7] S. Muravchick and R. J. Levy, “Clinical Implications of Mitochondrial Dysfunction,” Anesthesiology, Vol. 105, No. 4, 2006, pp. 819-837. doi:10.1097/00000542-200610000-00029
[8] V. A. Sardao, S. L. Pereira and P. J. Oliveira, “DrugInduced Mitochondrial Dysfunction in Cardiac and Skeletal Muscle Injury,” Expert Opinion on Drug Safety, Vol. 7, No. 2, 2008, pp. 129-146. doi:10.1517/14740338.7.2.129
[9] K. Nouette-Gaulain, P. Sirvent, M. Canal-Raffin, D. Morau, M. Malgat, M. Molimard, J. Mercier, A. Lacampagne, F. Sztark and X. Capdevila, “Effects of Intermittent Femoral Nerve Injections of Bupivacaine, Levobupivacaine, and Ropivacaine on Mitochondrial Energy Metabolism and Intracellular Calcium Homeostasis in Rat Psoas Muscle,” Anesthesiology, Vol. 106, No. 5, 2007, pp. 1026-1034. doi:10.1097/01.anes.0000265164.29630.b4
[10] I W. rwin, E. Fontaine, L. Agnolucci, D. Penzo, R. Betto, S. Bortolotto, C. Reggiani, G. Salviati and P. Bernardi, “Bupivacaine Myotoxicity Is Mediated by Mitochondria,” The Journal of Biological Chemistry, Vol. 277, No. 14, 2002, pp. 12221-12227. doi:10.1074/jbc.M108938200
[11] Q. Hogan, R. Dotson, S. Erickson, R. Kettler, K. Hogan, “Local Anesthetic Myotoxicity: A Case and Review,” Anesthesiology, Vol. 80, No. 4, 1994, pp. 942-927. doi:10.1097/00000542-199404000-00029
[12] A. Maslow and A. Lisbon, “Anesthetic Considerations in Patients with Mitochondrial Dysfunction,” Anesthesia & Analgesia, Vol. 76, No. 4, 1993, pp. 884-886. doi:10.1213/00000539-199304000-00035
[13] J. Finsterer, C. Haberler and J. Schmiedel, “Deterioration of Kearns-Sayre Syndrome Following Articaine Administration for Local Anesthesia,” Clinical Neuropharmacology, Vol. 28, No. 5, 2005, pp. 148-149. doi:10.1097/01.wnf.0000165352.10841.21
[14] V. A. Thompson and J. A. Wahr, “Anesthetic Considerations in Patients Presenting with Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS) Syndrome,” Anesthesia & Analgesia, Vol. 85, No. 6, 1997, pp. 1404-1406.
[15] V. Domingo-Triado, S. Selfa, F. Martinez, D. SanchezContreras, M. Reche, J. Tecles, M. T. Crespo, J. M. Palanca and B. Moro, “Ultrasound Guidance for Lateral Midfemoral Sciatic Nerve Block: A Prospective, Comparative, Randomized Study,” Anesthesia & Analgesia, Vol. 104, No. 5, 2007, pp. 1270-1274.
[16] F. Sztark, M. Malgat, P. Dabadie and J. P. Mazat, “Comparison of the Effects of Bupivacaine and Ropivacaine on Heart Cell Mitochondrial Bioenergetics,” Anesthesiology, Vol. 88, No. 5, 1998, pp. 1340-1349. doi:10.1097/00000542-199805000-00026
[17] F. Sztark, K. Nouette-Gaulain, M. Malgat, P. Dabadie and J. P. Mazat, “Absence of Stereospecific Effects of Bupivacaine Isomers on Heart Mitochondrial Bioenergetics,” Anesthesiology, Vol. 93, No. 2, 2000, pp. 456-462. doi:10.1097/00000542-200008000-00025

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.